| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A369 | Tanezumab Featured | Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia. |
|
| A370 | Fasinumab Featured | Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies. |
|
| A371 | MEDI-578 Featured |
|
|
| A372 | Fulranumab Featured | Fulranumab is a human IgG2 monoclonal antibody against nerve growth factor (NGF) and can be used for the research of pain. |
|
| A373 | AS2886401-00 Featured |
|
|
| A374 | Monalizumab Featured | Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC). |
|
| A375 | Tesnatilimab Featured | Tesnatilimab is a human IgG4 monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD). |
|
| A376 | Abbott patent anti-NGR Featured |
|
|
| A377 | Pfizer patent anti-Notch1 Featured |
|
|
| A378 | Tarextumab Featured | Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity. |
|
| DC67002 | Genentech patent anti-Notch Featured |
|
|
| A380 | Vesencumab Featured | Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer. |
|
| A381 | Uliledlimab Featured | Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer. |
|
| A382 | Oleclumab Featured | Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity. |
|
| A383 | Mupadolimab Featured | Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells. |
|
| A384 | Amgen patent anti-ORAI1 Featured |
|
|
| A385 | Vixarelimab Featured | Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash. |
|
| A386 | ASK8007 Featured |
|
|
| A387 | Janssen patent anti-CD200R1 Featured |
|
|
| A388 | Orticumab Featured | Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement. |
|
| A389 | Okayama U. patent anti-oxLDL Featured |
|
|
| A390 | Zelminemab Featured | Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor. |
|
| A391 | Lilly patent anti-PACAP Featured |
|
|
| A392 | Amgen patent anti-PAR-2 Featured |
|
|
| A393 | Anti-PAR2 Antibody (PAR650097) Featured |
|
|
| A394 | Regeneron patent anti-PAR-2 Featured |
|
|
| A395 | U.Penn. patent anti-PCLA Featured |
|
|
| A396 | Recaticimab Featured | Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Recaticimab can bind to PCSK9 and mediate its degradation, increasing the level of low-density lipoprotein (LDL) receptors on the surface of liver cells, reducing the level of LDL in plasma, thereby lowering blood lipids. Recaticimab can be used for the study of hypercholesterolemia. |
|
| A397 | Ralpancizumab Featured | Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke. |
|
| A398 | RG-7652 Featured |
|
